In a large observational study, semaglutide in obesity or type 2 diabetes mellitus (DM) was associated with a slightly lower risk of suicidal ideation compared to patients not taking a GLP-1 agonist. William Wang and others write about it in Nature Medicine.
Last summer the EMA, the European medicines watchdog, launched an investigation into a possible increased risk of, among other things, suicidal thoughts with semaglutide, after the pharmaceutical authority received reports in merit; as does, among other things, its American counterpart, the FDA.
Suicidal thoughts
Matched patients
For this study, American researchers compared the electronic medical records of more than 52,000 overweight or obese patients who were prescribed semaglutide (Wegovy) with the same number of corresponding patients who were prescribed a non-GLP-1 agonist against obesity, such as bupropion. . The researchers then repeated their analysis on more than 27,000 patients with type 2 diabetes who received semaglutide (Ozempic) with the same number of patients who were prescribed a non-GLP-1 agonist for type 2 diabetes, such as insulin. Investigations of suicidal thoughts are part of standard monitoring with semaglutide, the researchers write.
EMA
In the past, medicines aimed at weight reduction have often been withdrawn from the market due to the risk of suicidal thoughts and/or depressive symptoms, such as the drug rimonabant. The EMA has already received around 150 reports of semaglutide and suicidal thoughts or self-harm, which the authority is now investigating. It will meet on this in April.
Read also
2024-01-09 15:26:00
#risk #suicidal #ideation #appears #semaglutide